MAM
Truecaller elevates Rishit Jhunjhunwala to managing director
NEW DELHI: Caller ID app Truecaller has elevated chief product officer Rishit Jhunjhunwala to managing director, with immediate effect. The firm’s co-founder & CEO Alan Mamedi made the announcement via a post on professional networking site LinkedIn.
“I'm thrilled and proud to announce that Rishit Jhunjhunwala is taking on the role as our managing director, where he'll drive and inspire our fantastic team in India. Looking forward to 6+ more years buddy (sic),” Mamedi wrote.
Jhunjhunwala joined Truecaller in March 2015 as vice president – product. In June 2020, he was made chief product officer. During his tenure at the company, he has led app redesigns and helped develop features like spam activity indicator, call reason, schedule SMS and SMS translate, to name a few.
Prior to Truecaller, Jhunjhunwala co-founded the email service CloudMagic. He also had stints at July Systems and Verity Technologies.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
